Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1995-10-02
2000-02-08
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
424 111, 128659, 604 20, A61K 5110, A61B 600, A61N 130
Patent
active
060225211
ABSTRACT:
A method for determining the number of millicuries to be administered to a patient as a dose so as to establish a given centigray (cGy) dose to either the patient's lean body or the patient's total body. The method includes the steps of injecting a radioactive tracer into a patient, determining radiation levels in the whole body, calculating a geometric mean based on the radiation levels, determining the percent-injected activity remaining in the body at each time point, plotting the percent-injected activity versus calculated time from infusion on a log-linear graph, determining the effective half live and the rate of clearance from the log-linear graph, cross-indexing the effective half-life value with the patient's body weight, and multiplying the determined amount of therapeutic millicuries per centigray by the amount of desired centigray to be administered.
REFERENCES:
Robert Loevinger et alia, "A Revised Schema for Calculating the Absorbed Dose from Biologically DistrIbuted Radionuclides", Medical International Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine, Pamphlet No. 1, Revised, Mar., 1976, pp. 3-10.
"Importance of the Terminal Portion of Tumor Time-Activity Curve in Determining Tumor Dosimetry in Radioimmunotherapy", The Journal of Nuclear Medicine, vol. 32, No. 6, Jun. 1991, pp. 1314-1315.
Kaminski et alia, "Imaging, Dosimetry, and Radioimmunotherapy with Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma", Journal of Clinical Oncology, vol. 10, No. 11, Nov. 1992, pp. 1696-1711.
Zasadny et alia, "Standardized Uptake Values of Normal Tissues at Pet with 2-[Fluorine-18]-Fluoro-2-Deoxy-D-Glucose: Variations with Body Weight and a Method for Correction", Radiology, Dec. 1993, pp. 847-850.
Kaminski et alia, "Radioimmunotherapy of B-Cell Lymphoma with [.sup.131 l]Anti-B1 (Anti-CD20) Antibody", The New England Journal of Medicine, Aug. 12, 1993, pp. 459-465.
Koral et alia, "CT-Spect Fusion Plus Conjugate Views for Determining Dosimetry in Iodine-131-Monoclonal Antibody Therapy of Lymphoma Patients", The Journal of Nuclear Medicine, vol. 35, No. 10, Oct. 1994, pp. 1714-1720.
K.R. Zasadny et alia, Abstract for "Correlation of Dosimetric Parameters with Hematological Toxicity after Radioimmunotherapy of Non-Hodgkin's Lymphoma with I-131 Anti-B1. Utility of a New Parameter: Total Body Dose-Lean", The Journal of Nuclear Medicine, vol., 36, No. 5, May 1995, Abstract Book.
Wahl Richard L.
Zasadny Kenneth R.
Hartley Michael G.
Hollinden Gary E.
The Regents of the University of Michigan
LandOfFree
Method of establishing the optimal radiation dose for radiopharm does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of establishing the optimal radiation dose for radiopharm, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of establishing the optimal radiation dose for radiopharm will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1678448